Retatrutide Bali

Retatrutide in Bali

Explore Retatrutide, an investigational triple-receptor agonist targeting GLP-1, GIP and glucagon receptors. Learn about clinical research, weight-loss results, product specifications and availability in Bali.

  • Triple Agonist
  • GLP-1 / GIP / Glucagon
  • 32 mg Pen
  • Clinical Research
32 mg pen
IDR 4,000,000

What Is Retatrutide?

Retatrutide is an experimental peptide medicine. A single molecule activates three receptors that help the body respond to food and regulate energy use. An agonist is a substance that switches on a receptor. “Triple” describes the three targets, rather than a mixture of three drugs.

Researchers are studying whether acting on these pathways together can change body weight and metabolic outcomes in people with obesity. The retatrutide used in the trials was supplied by the study sponsor. The studies do not establish the identity or performance of a separately branded pen.

GLP-1 · Appetite regulation

Glucagon-like peptide-1 signals fullness and helps regulate insulin release when blood glucose rises.

GIP · Metabolic signaling

Glucose-dependent insulinotropic polypeptide helps the pancreas respond to a meal. Its receptor is a second target shared with tirzepatide.

Glucagon · Energy metabolism

Glucagon helps the liver make glucose available. Researchers are also investigating its contribution to energy expenditure.

How Does Retatrutide Work?

The receptor targets are known. To understand their contributions, it helps to distinguish what scientists saw in the laboratory from what they measured in people.

Receptor activation

One retatrutide molecule can activate the GLP-1, GIP, and glucagon receptors. Laboratory tests characterize the activity at each target.

Appetite regulation

GLP-1 signaling can increase fullness and reduce food intake. Hunger and satiety also depend on many signals beyond these three receptors.

Glucose and energy use

GIP contributes to glucose-dependent insulin release. Coskun and colleagues found that glucagon-receptor activity increased energy expenditure in mice. How much that pathway contributes to weight change in people remains uncertain.

Weight-management trials

Investigators assign participants to retatrutide or a comparator and measure changes in body weight. That comparison captures the combined effect of the molecule. It cannot attribute a fraction of a person’s weight change to each receptor.

RetatrutideGLP-1 + GIP + glucagon receptorsSignals affecting appetite and metabolismBody-weight change measured in trials

Retatrutide Weight Loss Results: What Clinical Trials Show

In the 2023 phase 2 trial, Jastreboff and colleagues enrolled 338 adults with obesity or overweight and a weight-related condition. Participants received retatrutide or placebo. Week 24 was the primary endpoint. Week 48 provided a longer look at the same groups.

24.2%

Estimated average weight reduction at week 48 in the 12 mg research group. The placebo group averaged a 2.1% reduction.

Mean body-weight change from baseline in the 2023 phase 2 trial. The 4 mg and 8 mg columns each combine the trial’s two groups with the same target dose. Negative values indicate weight loss.
  • 1 mg−8.7%
  • 4 mg (pooled)−17.1%
  • 8 mg (pooled)−22.8%
  • 12 mg−24.2%
  • Placebo−2.1%
See all published values in the chart
Trial measure1 mg4 mg (pooled)8 mg (pooled)12 mgPlacebo
Baseline0%0%0%0%0%
Week 24−7.2%−12.9%−17.3%−17.5%−1.6%
Week 48−8.7%−17.1%−22.8%−24.2%−2.1%
View the published data

Retatrutide 24-week results

At the primary endpoint, average weight reductions ranged from 7.2% in the 1 mg group to 17.5% in the 12 mg group. The placebo group averaged 1.6%. The chart includes every published target-dose group.

Retatrutide 48-week results

The groups continued to diverge after week 24. By week 48 the combined 4 mg and 8 mg groups averaged reductions of 17.1% and 22.8%. The same paper reported 24.2% for the 12 mg group.

What the results mean

The percentages describe estimated changes from each group’s own starting weight. The 24.2% figure includes the entire change in the 12 mg group. Subtracting the placebo group’s change answers a different question.

Phase 3 evidence from TRIUMPH-1

In the separate 2026 TRIUMPH-1 publication, 2,339 adults underwent randomization. At week 80, the intention-to-treat analysis reported weight changes of −17.6%, −23.7%, and −25.0% in the 4 mg, 9 mg, and 12 mg groups, respectively, and −3.9% with placebo. These are results from a new study.

Limitations of the studies

Participants met specific entry criteria and had scheduled follow-up. Group averages conceal variation among individuals. The phase 2 study lasted 48 weeks and could not establish the frequency of rare harms or the effect of the drug over many years. Neither trial tested the pictured Body Pharm pen.

Retatrutide Weight Loss Calculator — Explore Clinical Trial Results

Choose your starting weight and a published time point. Compare the recorded group averages in kilograms or pounds.

kg

Average weight change

24.2%
Starting weight
90 kg
Equivalent weight difference
21.8 kg
Calculated remaining weight
68.2 kg

This is a mathematical illustration of a published clinical trial average, not a prediction of your personal results.

Where these figures come from

Selected group: 12 mg research group.

View the published results

Retatrutide vs Tirzepatide: What’s the Difference?

Both molecules target GIP and GLP-1. A third target, the glucagon receptor, distinguishes retatrutide. Their clinical and regulatory histories differ as well.

FeatureRetatrutideTirzepatide
Drug classTriple receptor agonistDual receptor agonist
GLP-1 receptorYesYes
GIP receptorYesYes
Glucagon receptorYesNo
Weight-management evidencePlacebo-controlled phase 2 and phase 3 trialsMultiple phase 3 trials, including SURMOUNT-1
US regulatory statusInvestigationalSpecific Mounjaro and Zepbound products have FDA approval

How Their Mechanisms Differ

Tirzepatide acts on two incretin receptors. Retatrutide adds glucagon-receptor activity. The number of targets alone cannot tell us which medicine produces a larger change in weight or a different pattern of adverse effects.

What Clinical Trials Have Found

Each molecule has produced greater average weight loss than placebo in trials enrolling adults with obesity. Retatrutide’s phase 2 study and tirzepatide’s SURMOUNT-1 study randomized participants separately.

Why Results Cannot Be Directly Compared

Eligibility, follow-up, and statistical methods differed across those studies. The direct retatrutide–tirzepatide comparison is TRIUMPH-5. Its registry listed no results when this guide was reviewed in November 2026.

Retatrutide Side Effects and Regulatory Status

Digestive symptoms were the most common side effects in the phase 2 study and were usually mild or moderate. Investigators also measured a dose-related rise in heart rate that peaked at week 24 and declined over the remainder of follow-up.

Where approval stands

FDA identifies retatrutide as an ingredient in no FDA-approved drug. The developer describes access to its investigational product through clinical trials. No BPOM registration has been verified for the Body Pharm 32 mg pen in Indonesia.

Retatrutide Pen — Product Specifications

Look for RETATRUTIDE 32 on both the box and the pen. The photograph of the selector shows the same pen from the other end.

Retatrutide 32 mg — Product Details

SpecificationDetails
ProductRetatrutide
BrandBody Pharm
FormatPrefilled pen
Total per pen32 mg
Price per penIDR 4,000,000
Storage on the label2–8°C, protected from light

Product gallery

View the original pen photograph

Quality Documentation

You can read the manufacturer’s report here. To check your own carton, ask for the document with the same batch number as the box.

Storage Information

The label gives a storage range of 2–8°C. Keep the carton away from light and the freezer. If it arrives warm or damaged, keep the packaging and contact the team before using it.

Your delivery estimate

32 mg · IDR 4,000,000
Individual pens
1
Pen subtotal
IDR 4,000,000
Bali delivery
IDR 100,000
Estimated total
IDR 4,100,000
Confirm this estimate on WhatsApp

Explore Our Peptide Pen Collection

See the amount and price for each complete pen.

Bali Delivery & Storage Information

Where we deliver
Express areas include Canggu, Seminyak, Kerobokan, Umalas, Uluwatu and Sanur. For another address, send a map pin so the team can check the route.
Cost and timing
One or two pens cost IDR 100,000 to deliver. Delivery is free for three or more pens in the same order. Allow 2–4 hours in the express areas after the team confirms your order.
How to pay
Pay cash in Indonesian rupiah on delivery, or arrange a USDT payment with the Bali team. Confirm the amount when you book.
Receiving the parcel
The courier brings an insulated parcel with gel packs. On arrival, refrigerate the pen at 2–8°C, protected from light. Do not freeze.

Frequently Asked Questions About Retatrutide

What is Retatrutide?

Retatrutide is an investigational peptide that activates the receptors for GLP-1, GIP, and glucagon. Researchers are studying its effects on body weight and other metabolic outcomes. In obesity trials it has been compared with placebo under controlled conditions. The 32 mg label on the Body Pharm pen describes a separate catalog item.

How does Retatrutide work?

Retatrutide acts on three hormone receptors. GLP-1 and GIP are involved in the body’s response to eating, and glucagon signals the liver to make glucose available. Preclinical experiments also suggest a role for energy expenditure. Human trials measure the overall response to the molecule. They cannot separate out how much weight change comes from each receptor.

Is Retatrutide a GLP-1 medication?

It has GLP-1 receptor activity. Calling it a triple agonist gives a fuller description because it also activates GIP and glucagon receptors. Single-target GLP-1 medicines and investigational retatrutide have different sets of receptors and different regulatory histories.

What is a triple agonist?

An agonist activates a receptor, a protein that receives a signal in the body. A triple agonist can activate three kinds of receptor. In this case one peptide has activity at the GLP-1, GIP, and glucagon receptors. The term describes its targets. It carries no claim about the size of an individual's response.

How is Retatrutide different from Tirzepatide?

Both activate GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor and remains investigational. Specific tirzepatide products have approvals for defined indications. The phase 2 retatrutide trial and the 72-week SURMOUNT-1 tirzepatide trial used different participants and designs. TRIUMPH-5 is the registered direct comparison of the two molecules.

What do Retatrutide clinical trials show?

The 2023 phase 2 trial found greater average weight reductions with retatrutide than placebo at both 24 and 48 weeks. A separate phase 3 trial, TRIUMPH-1, reported an average 25.0% reduction in its 12 mg group at week 80 and 3.9% with placebo in the intention-to-treat analysis. Group results depend on the study population and follow-up.

What were the 48-week results?

In the phase 2 trial, estimated mean weight reductions were 8.7% in the 1 mg group, 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group. Placebo averaged 2.1%. The milligram labels identify study groups. The percentages refer to change from starting body weight.

What are the known side effects?

Digestive symptoms, including nausea, diarrhea, vomiting, and constipation, were reported in the phase 2 trial. Most were mild or moderate and occurred more often in higher-dose groups. The investigators also recorded increases in heart rate. A trial of this size and duration provides limited information about uncommon or long-term adverse effects.

Is Retatrutide FDA-approved?

No. FDA says retatrutide is not an ingredient in any FDA-approved drug. Published studies and a phase 3 development program establish that the molecule is being investigated. They do not authorize commercial pens labeled with its name. The references include FDA’s current notice on unapproved products.

Is Retatrutide available as a prefilled pen?

The Bali catalog pictures a Body Pharm prefilled pen labeled “Retatrutide 32 mg.” Lilly describes its investigational retatrutide as available through its clinical trials. The catalog listing and photographs do not establish that the pen is sponsor-supplied trial medication or authorized for human use.

What does 32 mg mean on the product label?

It is the manufacturer’s stated total amount in the entire pen. The number does not state the amount delivered in a particular injection or how long a pen would last. It is a packaging specification, and it serves a different purpose from the target-group labels used in the research chart.

How can I verify product documentation?

The manufacturer’s certificate shown here identifies lot C-Re32-2.4-20251011. Compare that exact code with the lot on the supplied pack. The report lists separate results for identification, purity, sterility, and bacterial endotoxins. Each result concerns the submitted sample. The certificate cannot authenticate a different lot or establish an Indonesian marketing authorization.

What storage conditions does the manufacturer specify?

For lot C-Re32-2.4-20251011, the Body Pharm certificate specifies a sealed container in a dark place at 2–8°C and says to avoid freezing. Check the instructions and expiry on the supplied pack. The report documents the manufacturer’s storage conditions for the named lot.

What is the regulatory status of Retatrutide in Indonesia?

We could not verify an Indonesian BPOM marketing authorization for the Body Pharm Retatrutide 32 mg pen. Lilly describes its retatrutide as investigational. BPOM’s public medicines database lets readers check the product name, registration holder, presentation, and registration number. A contact or listing in Bali does not establish approval.

Where can I read the original clinical studies?

Jastreboff and colleagues published the 2023 phase 2 trial and the 2026 TRIUMPH-1 trial in the New England Journal of Medicine. Their article records appear in the references below. ClinicalTrials.gov record NCT04881760 describes the phase 2 protocol. For the direct comparison with tirzepatide, consult NCT06662383.

Open the full FAQ

Retatrutide Research & References

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

A. M. Jastreboff, L. M. Kaplan, et al.

2023 · Randomized, double-blind, placebo-controlled phase 2 trial · 338 adults · 48 weeks

The primary endpoint was body-weight change at week 24. At week 48, mean weight change ranged from −8.7% to −24.2% in active groups and was −2.1% with placebo.

Read Original Study

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1)

A. M. Jastreboff, L. M. Kaplan, et al.

2026 · Randomized, double-blind phase 3 trial · 2,339 randomized · 80 weeks

The intention-to-treat analysis estimated −25.0% body-weight change in the 12 mg group and −3.9% with placebo. This is a separate population from the phase 2 study.

Read Original Study

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

T. Coskun, S. Urva, et al.

2022 · Receptor assays, animal experiments, and first-in-human phase 1 study · 45 healthy volunteers in the human study · Human follow-up to day 43

Experiments identified three receptor targets. Increased energy expenditure was observed in mice. The early human study examined tolerability and exposure.

Read Original Study

ClinicalTrials.gov · Phase 2 retatrutide obesity trial (NCT04881760)

Eli Lilly and Company, study sponsor

2021, first posted · Trial registry record · 338 enrolled · 48-week treatment period

The registration identifies the treatment arms, inclusion criteria, and prespecified 24- and 48-week weight endpoints.

View the trial record

ClinicalTrials.gov · TRIUMPH-5 (NCT06662383)

Eli Lilly and Company, study sponsor

2024, first posted · Phase 3 direct-comparison trial registration · 800 planned · Through week 80 for the primary endpoint

This trial compares retatrutide with tirzepatide in adults with obesity. No results were posted in the registry at review in November 2026.

View the trial record

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

US Food and Drug Administration

2026 · Regulatory safety communication · Regulatory information · No study period

FDA identifies retatrutide as an ingredient in no FDA-approved drug. The notice distinguishes approved medicines from products sold under an ingredient name.

Read the official information

Cek Produk · Indonesian medicines register

Badan Pengawas Obat dan Makanan (BPOM)

Accessed November 2026 · National product register · Product-level records · Continuously updated

Check an exact medicine by its registered name and registration number. A BPOM authorization for this Body Pharm pen has not been verified.

Open the Indonesian medicines register

What to Know About Retatrutide

Eli Lilly and Company, investigational product developer

Updated October 2026 · Sponsor development and access statement · Clinical development program · Status as of October 2026

The developer describes retatrutide as investigational and limits access to its trial medicine to clinical trial participants.

Read the developer’s information

Before you order

Read the Retatrutide buying guide

Ask the Bali team

Tell us how many Retatrutide pens you want and where in Bali you are staying. We can confirm availability, the delivered price and a time that works for you.

Contact on WhatsApp